Delta opioid modulation of the binding of guanosine-5'-O-(3- [35S]thio)triphosphate to NG108-15 cell membranes: Characterization of agonist and inverse agonist effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1276-1284

  Szekeres, Philip G ^a   Traynor, John R ^a,b  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DELTORPHIN; DIPRENORPHINE; ENADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ETORPHINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; LEUCINE ENKEPHALIN[2 DEXTRO SERINE 6 THREONINE]; LEVALLORPHAN; MAGNESIUM ION; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALORPHINE; NALTREXONE; NALTRIBEN; NALTRINDOLE; PERTUSSIS TOXIN; POTASSIUM ION; RECEPTOR SUBTYPE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GLIOMA CELL; MEMBRANE BINDING; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BENZYLIDENE COMPOUNDS; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALIN, LEUCINE; ENKEPHALINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MICE; NALTREXONE; NEUROBLASTOMA; RATS; RECEPTORS, OPIOID, DELTA; SODIUM;

EID: 0031456986     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. BIRNBAUMER, L., ABRAMOWITZ, J. AND BROWN, A. M.: Receptor-effector coupling by G proteins. Biochim. Biophys. Acta 1031: 163-224, 1990.
2. BOKOCH, G. M., KATADA, T., NORTHUP, J. K., UI, M. AND GILMAN, A. G.: Purification and properties of the inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. J. Biol. Chem. 259: 3560-3567, 1984.
3. 2+ current in NG108-15 neuroblastoma cells via a pertussis toxin sensitive mechanism. Br. J. Pharmacol. 106: 231-232, 1992.
4. 32P]GTP labeling of multiple G protein alpha subunits. J. Neurochem. 64: 2534-43, 1995.
5. CHILDERS, S. R., FLEMING, L. M., SELLEY, D. E., MCNUTT, R. W. AND CHANG, K. J.: BW373U86: A nonpeptidic δ-opioid agonist with novel receptor/G protein-mediated actions in rat brain and neuroblastoma cells. Mol. Pharmacol. 44: 827-834, 1993.
6. CHILDERS, S. R. AND SNYDER, S. H.: Differential regulation by guanine nucleotides of opiate agonist and antagonist receptor interactions. J. Neurochem. 34: 583-593, 1980.
7. COSTA, T. AND HERZ, A.: Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 86: 7321-7325, 1989.
8. COSTA, T., LANG, J., GLESS, C. AND HERZ, A.: Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: Specific regulation by antagonists and sodium ions. Mol. Pharmacol. 37: 383-394, 1990.
9. COSTA, T., OGINO, Y., MUNSON, P. J., ONARAN, H. O. AND RODBARD, D.: Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 41: 549-560, 1992.
10. 4]enkephalin as a highly selective ligand for the delta binding site. Br. J. Pharmacol., 85: 927-932, 1985.
11. EMMERSON, P. J., CLARK, M. J., MANSOUR, A., AKIL, H., WOODS, J. H. AND MEDZIHRADSKY, F.: Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J. Pharmacol. Exp. Ther. 278: 1121-1127, 1996.
12. EVANS, C. J., KEITH, D. E., MORRISON, H., MAGENDZO, K. AND EDWARDS, R. H.: Cloning of a delta opioid receptor by functional expression. Science 258: 1952-1955, 1992.
13. GIERSCHIK, P., MOGHTADER, R., STRAUB, C., DIETERICH, K. AND JAKOBS, K. H.: Signal amplification in HL-60 granulocytes: Evidence that the chemotactic peptide receptor catalytically activates guanine-nucleotide-binding regulatory proteins in native plasma membranes. Eur. J. Biochem. 197: 725-731, 1991.
14. 2-adrenergic, muscarinic, and opiate receptors. Mol. Pharmacol. 43: 434-443, 1993.
15. 2+ and the βγ-subunit complex on the interactions of guanine nucleotides with G proteins. J. Biol. Chem. 262: 762-766, 1987.
16. HILF, G., GIERSCHIK, P. AND JAKOBS, K. H.: Muscarinic acetylcholine receptorstimulated binding of guanosine 5′-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes. Eur. J. Biochem. 186: 725-731, 1989.
17. HO, B. Y., HOLMES, B. B., ZHOA, J. AND FUJIMOTO, J.: Determination of delta opioid receptors in NG108-15 cells. Eur. J. Pharmacol. 319: 109-114, 1997.
18. KATADA, T., OINUMA, M. AND UI, M.: Mechanism for inhibition of the catalytic activity of adenylate cyclase by the guanine nucleotide-binding proteins serving as the substrate of islet-activating protein, pertussis toxin. J. Biol. Chem. 261: 5215-5221, 1986.
19. KELLY, P. D., RANCE, M. J. AND TRAYNOR, J. R.: Properties of opiate binding in the rat spinal cord. Neuropeptides 2: 319-324, 1982.
20. KENAKIN, T.: The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev. 48: 413-463, 1996.
21. KIEFFER, B. L., BEFORT, K., GAVERIAUX-RUFT, C. AND HIRTH, C. G.: The δ-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89: 12048-12052, 1992.
22. KOSTERLITZ, H. W. AND WATT, A. J.: Kinetic parameters of narcotic agonists and antagonists with particular reference to N-allylnoroxymorphone (naloxone). Br. J. Pharmacol. 33: 266-270, 1968.
23. LAUGWITZ, K.-L., OFFERMANNS, S., SPICHER, K. AND SCHULTZ, G.: μ and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 10: 233-242, 1993.
24. LAW, P. Y., HOM, D. S. AND LOH, H. H.: Opiate regulation of adenosine 3′:5′-cyclic monophosphate level in neuroblastoma X glioma NG108-15 hybrid cells: Relationship between receptor occupancy and effect. Mol. Pharmacol. 23: 26-35, 1983.
25. LAW, P. Y., MCGINN, T. M., WICK, M. J., ERIKSON, L. J., EVANS, C. J. AND LOH, H. H.: Analysis of delta opioid receptor activities stably expressed in CHO cell lines: Function of receptor density? J. Pharmacol. Exp. Ther. 271: 1686-1694, 1994.
26. LAZARENO, S., BUCKLEY, N. J. AND ROBERTS, F. P.: Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol. Pharmacol. 38: 805-815, 1990.
27. LAZARENO, S., FARRIES, T. AND BIRDSALL, N. J. M.: Pharmacological characterisation of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors m1-m4. Life Sci. 52: 449-456, 1993.
28. LEFKOWITZ, R. J., COTECCHIA, S., SAMANA, P. AND COSTA, T.: Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14: 303-307, 1993.
29. LESLIE, F. M.: Methods used for the study of opioid receptors. Pharmacol. Rev. 39: 197-249, 1987.
30. 35S]thio)triphosphate binding. Mol. Pharmacol. 44: 115-123, 1993.
31. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
32. MACKIE, K., DEVANE, W. A. AND HILLE, B.: Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44: 498-503, 1993.
33. MATTIA, A., FARMER, S. C., TAKEMORI, A. E., SULTANA, M., PORTOGHESE, P. S., MOSBERG, H. I., BOWEN, W. D. AND PORRECA, F.: Spinal opioid delta antinociception in the mouse: Mediation by a 5′-NTII-sensitive delta receptor subtype. J. Pharmacol. Exp. Ther. 260: 518-525, 1992.
34. i2. FEBS Lett. 269: 430-434, 1990.
35. i2. Biochem. J., 267: 391-398, 1990.
36. MICHEL, A. D., DELMENDO, R., STEFANICH, E. AND WHITING, R. L.: Binding characteristics of the muscarinic receptor subtype of the NG108-15 cell line. Naunyn-Schmiedeberg's Arch Pharmacol. 340: 62-67, 1989.
37. MULLANEY, I., CARR, I. C. AND MILLIGAN, G.: Analysis of inverse agonism at the S opioid receptor after expression in rat 1 fibroblasts. Biochem. J. 315: 227-234, 1996.
38. MUNSON, P. AND RODBARD, D.: LIGAND: A versatile computerised approach for characterisation of ligand binding systems. Anal. Biochem. 107: 220-239 1980.
39. i2, in membranes of neuroblastoma X glioma (NG108-15) hybrid cells. J. Biol. Chem. 266: 3365-3368, 1991.
40. q/11. Mol. Pharmacol. 45: 890-898, 1994.
41. PORRECA, F., BILSKY, E. J. AND LAI, J.: Pharmacological characterisation of δ- and κ- receptors. In The Pharmacology of Opioid Peptides, ed. by L. F. Tseng, pp. 219-248, Harwood Academic Publishers, Germany, 1995.
42. 1-opioid receptor antagonist: 7-Benzylidenenaltrexone. Eur. J. Pharmacol. 218: 195-196, 1992.
43. PRATHER, P. L., LOH, H. H. AND LAW, P. Y.: Interaction of 6-opioid receptors with multiple G proteins: A nonrelationship between agonist potency to inhibit adenylyl cyclase and to activate G proteins. Mol. Pharmacol. 45: 997-1003, 1994.
44. RODBELL, M., BIRNBAUMER, L., POHL, S. L. AND KRANS, H. M.: The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action. J. Biol. Chem. 246: 1877-82, 1971.
45. RODBELL, M.: The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature 284: 17-22, 1980.
46. 2+ and other divalent cations on the binding of tritiated opioid ligands. J. Neurochem. 59: 467-472, 1992.
47. ROERIG, S. C., LOH, H. H. AND LAW, P. Y.: Identification of three separate guanine nucleotide-binding proteins that interact with the δ-opioid receptor in NG108-15 neuroblastoma X glioma hybrid cells. Mol. Pharmacol. 41: 822-831, 1992.
48. ROERIG, S. C., WILLIAMS, C. L., HRUBY, V. J., BURKS, T. F. AND ROSENFELD, G. C.: Inhibition of adenyly cyclase by the cholecystokinin analog SNF 9007 in neuroblastoma X glioma NG108-15 hybrid cells. Regul. Peptides 61: 51-56, 1996.
49. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci U.S.A. 92: 7242-6, 1995.
50. SOFUOGLU, M., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Differential antagonism of delta opioid agonists by naltrindole (NTI) and its benzofuran analog (NTB) in mice: Evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257: 676-680, 1991.
51. STANDIFER, K. M., CLARK, J. A. AND PASTERNAK, G. W.: Modulation of mu-1 opioid binding by magnesium: Evidence for multiple receptor conformations. J. Pharmacol. Exp. Ther. 266: 106-113, 1993.
52. STAPELFELD, A., HAMMOND, D. L. AND RAFFERTY, M. F.: Antinociception after intracerebroventricular administration of naltrindole in the mouse. Eur. J. Pharmacol. 214: 273-276, 1992.
53. STERNWEIS, P. C., NORTHUP, J. K., SMIGEL, M. D. AND GILMAN, A. G.: The regulatory component of adenylate cyclase. J. Biol. Chem. 256: 11517-11526, 1981.
54. 35S]GTPγS binding in membranes from NG108-15 neuroblastoma X glioma cells. Analgesia 1: 778-780, 1995.
55. 2-adrenergic receptor activation of G proteins: Evidence for a precoupled receptor/G protein state. Mol. Pharmacol. 45: 524-531, 1994.
56. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47: 848-854, 1995.
57. WIELAND, T., KREISS, J., GIERSCHIK, P. AND JAKOBS, K. H.: Role of GDP in formyl-peptide-receptor-induced activation of guanine-nucleotide-binding proteins in membranes of HL 60 cells. Eur. J. Biochem. 205: 1201-1206, 1992.